Handbook_Volume III

103 Bibliografia [1] Ren X, Huang Q, Qu Q, Cai X, Fu H, Mo X, et al. Predicting mortality from intracranial hemorrhage in patients who undergo allogeneic hematopoietic stem cell transplantation. Blood Adv 2021;5(23):4910-4921 [2] Kao RL, Holtan SG. Host and graft factors impacting infection risk in hematopoietic cell transplantation. Infect Dis Clin North Am. 2019;33:311-329 [3] Leliefeld PH, Wessels CM, Leenen LP, Koenderman L, Pillay J. The role of neutrophils in immune dysfunction during severe inflammation. Crit Care 2016;20:73 [4] Gea-Banacloche JC, Wade JC. Improvements in the prevention and management of infectious complications after hematopoietic stem cell transplantation. Cancer Treat Res. 2009;144:539-573 [5] Young JH. Management of infectious diseases in stem cell transplantation and hematologic malignancy. Infect Dis Clin North Am. 2019;33:xiii-xv [6] Verlinden A, Mikulska M, Knelange NS, Averbuch D, Styczynski J. Current antimicrobial practice in febrile neutropenia across Europe and Asia: the EBMT Infectious Disease Working Party. Bone Marrow Transplant. 2020;55:1588-1594 [7] Gyssens IC, Kern WV, Livermore DM, ECIL-4, a joint venture of EBMT, EORTC, ICHS and ESGICH of ESCMID. The role of antibiotic stewardship in limiting antibacterial resistance among hematology patients. Haematologica. 2013;98:1821–1825 [8] Mercier T, Maertens J. Clinical considerations in the early treatment of invasive mould infections and disease. J Antimicrob Chemother. 2017;72(suppl_1):i29–38 [9] Marr KA, Schlamm HT, Herbrecht R, et al. Combination antifungal therapy for invasive aspergillosis: a randomized trial. Ann Intern Med. 2015;162:81–89 [10] Girmenia C, Raiola AM, Piciocchi A, et al. Incidence and outcome of invasive fungal diseases after allogeneic stem cell transplantation: a prospective study of the Gruppo Italiano Trapianto Midollo Osseo (GITMO). Biol Blood Marrow Transplant. 2014;20:872–80 [11] Tissot F, Agrawal S, Pagano L, et al. ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients. Haematologica. 2017;102:433–44 [12] Ljungman P, de la Camara R, Robin C, Crocchiolo R, Einsele H, Hill JA, et al. Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukemia (ECIL 7). Lancet Infect Dis. 2019;19(8):e260-272 [13] Marty FM, Ljungman P, Chemaly R, Maertens J, Dadwal SS, Duarte RF, et al. Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation. N Eng J Med 2017;377:24332444 [14] Wayne Liu L, Yn A, Gao F, Olson M, Crain M, Abboud R, et al. Letermovir discontinuation at Day 100 After Allogeneic Stem Cell Transplant is associated with Increased CMV-related Mortality. Transplant Cell Ther 2022;28(2):510.e1-510.e9 [15] Hirsch HH, Martino R, Ward KN, Boeckh M, Einsele H, Ljungman P. Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis and treatment of human respiratory syncytial virus, parainfluenza virus, metapneumovirus, rhinovirus, and coronavirus. Clin Infect Dis. 2013;56: 258–66 [16] Sung AD, Hassan S, Cardona DM, Wild D, Nichols KR, Mehdikhani H, et al. Late Gastrointestinal Complications of Allogeneic Hematopoietic Stem Cell Transplantation in Adults. Transpl Cell Therapy 2018;24(4):734-740 [17] Nesher L, Rolston KVI. Neutropenic Enterocolitis, a Growing Concern in the Era of Widespread use of Aggressive Chemotherapy. Clin Infect Dis 2013;56:711-717 [18] Bonifazi F, Barbato F, Ravaioli F, Sessa M, Defrancesco I, Arpinati M, et al. Diagnosis and treatment of VOD/SOS After Allogeneic Hematopoietic Stem Cell Transplantation. Front Immunol 2020;11:489 [19] Richardson PG, Riches ML, Kernan NA, Brochstein JA, Mineishi S, Termuhlen AM, et al. Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure. Blood 2016;127:1656-1665 [20] Corbacioglu S, Carreras E, Mohty M, Pagliuca A, Boelens JJ, Damaj G, et al. Defibrotide for the Treatment of Hepatic Veno-Occlusive Disease: Final Results from the international Compassionate-Use Program. Biol Blood Marrow Transplant 2016;22:1874.1882 [21] Mallet V, van Bömmel F, Doerig C, et al. Management of viral hepatitis in patients with haematological malignancy and in patients undergoing haemopoietic stem cell transplantation: recommendations of the 5th European Conference on Infections in Leukaemia (ECIL-5). Lancet Infect Dis. 2016;16:606–17 [22] De Padua Silva L, Patah PA, Saliba RM, Szewczyk NA, Gilman L, Neumann J, et al. Hemorrhagic cystitis after allogeneic hematopoietic stem cell transplants is the complex result of BK virus infection, preparative regimen intensity and donor type. Haematologica. 2010;95(7):1183-1190 [23] Young JA, Pallas CR, Knovich MA. Transplant-associated thrombotic microangiopathy: theoretical considerations and a practical approach to an unrefined diagnosis. Bone Marrow Transplant 2021;56:1805-1817 [24] Jodele S. Complement pathophysiology and treatment of transplant-associated thrombotic microangiopathies. Semin Hematol 2018;55:159-166 [25] Jodele S, Dandoy CE, Lane A, Laskin BL, Teusink-Cross A, Myers KC, et al. Complement blockade for TA-TMA: lessons learned from a large pediatric cohort treated with eculizumab. Blood 2020;135:1049-1057 [26] Reddy P, Johnson K, Uberti P, Reynolds C, Silver S, Ayash L, et al. Nephrotic syndrome associated with Chronic graft-versushost disease after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2006;38(5):351-357 [27] Bergeron A, Chevret S, Peffault de la Tour R, Chagnon K, de Margerie-Mellon C, Riviere F, et al. Noninfectious lung complications after allogeneic haematopoietic stem cell transplantation. European Resp Journal 2018;51:1702617 [28] Patel S, Ahn KW, Khanal M, Bupp C, Allbee-Johnson M, Majhail NS, et al. Noninfectious Pulmonary Toxicity after Allogeneic Hematopoietic Cell Transplantation. Transplant Cell Ther 2022;28(6):310-320 [29] Ferrara JLM, Levine JE, Reddy P, Holler E. Graft-versus-host disease. Lancet 2009;373:1550-1561 [30] Jagasia M, Arora M, Flowers ME, Chao NJ, McCarthy CS, Cutler CS, et al. Risk factors for acute GVHD and survival after hematopoietic cell transplantation. Blood 2012;119:296-307 [31] Pidala J, Wang T, Haagenson M, Spellman SR, Askar M, Battiwalla M, et al. Amino acid substitution at peptide-binding pockets of HLA class I molecules increases risk of severe acute GVHD and mortality. Blood 2013;122:3651-3658 [32] Storb R, Deeg JH, Whitehead J, Appelbaum F, Beatty P, Bensinger W, et al. Methotrexate and Cyclosporine Compared with Cyclosporine Alone for Prophylaxis of Acute Graft versus Host Disease after Marrow Transplantation for Leukemia. N Eng J Med 1986;314:729-735 [33] Ratanatharathorn V, Nash RA, Przepiorka D, Devine SM, Klein JL, Weisdorf D, et al. Phase III Study Comparing Metho1. Aspetti Generali